ipro2 (Medtronic inc)
90
Structured Review
Medtronic inc
ipro2
Ipro2, supplied by Medtronic inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ipro2/ipro2+cgm+system/pmc11674695-12-6-6
Average 90 stars, based on 1 article reviews
Ipro2, supplied by Medtronic inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ipro2/ipro2+cgm+system/pmc11674695-12-6-6
Average 90 stars, based on 1 article reviews
ipro2 - by Bioz Stars,
2026-09
90/100 stars
Images
1) Product Images from "Continuous Glucose Monitoring—New Diagnostic Tool in Complex Pathophysiological Disorder of Glucose Metabolism in Children and Adolescents with Obesity"
Article Title: Continuous Glucose Monitoring—New Diagnostic Tool in Complex Pathophysiological Disorder of Glucose Metabolism in Children and Adolescents with Obesity
Journal: Diagnostics
doi: 10.3390/diagnostics14242801
Figure Legend Snippet: Cross-sectional clinical studies with CGM in children and adolescent populations with obesity.
Techniques Used: Comparison, Diagnostic Assay
Related Articles
Comparison:Article Title: Defining continuous glucose monitor time in range in a large community-based cohort without diabetes. Article Snippet: Our observed proportion of time spent >180mg/dL was not shown in some smaller studies of 25 normoglycemic adults (n<100) wearing Dexcom G6 sensors by Shah et al.(3) or Abbott’s Freestyle Libre Pro 26 factory-calibrated sensors. (10) However, other studies have observed participants without diabetes achieving 27 glucose levels >180mg/dL, using the Freestyle Libre and iPro2 (Medtronic). (11-13) Direct comparisons are 28 AC CE PT ED M AN US CR IP T D ow nloaded from https://academ ic.oup.com /jcem /advance-article/doi/10.1210/clinem /dgae626/7754867 by guest on 12 Septem ber 2024 difficult because these studies did not always report the average times spent in those ranges. Article Title: Enlarged glycemic variability in sulfonylurea-treated well-controlled type 2 diabetics identified using continuous glucose monitoring Article Snippet: The CGM devices used were Gold (CGMS System Gold, Medtronic Inc.; Fridley, MN) and iPro2 (Medtronic MiniMed Inc.; Northridge, CA). Article Title: Effect of a single bout of morning or afternoon exercise on glucose fluctuation in young healthy men Article Snippet: The day before beginning each trial, a CGMs (iPro2, Medtronic MiniMed, CA) was attached to each subject. Article Title: Real-time CGM Is Superior to Flash Glucose Monitoring for Glucose Control in Type 1 Diabetes: The CORRIDA Randomized Controlled Trial Article Snippet: All participants initiated professional (masked) CGM (iPro2; Medtronic, Inc.) and were then monitored for 6 days. Article Title: Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver disease. Article Snippet: Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver disease Yutaro Ogawa,* Takashi Nakahara,* Masafumi Ono, Takumi Kawaguchi, Hiroshi Isoda, Akira Hiramatsu,* Shinsuke Uchikawa,* Hatsue Fujino,* Eisuke Murakami,* Tomokazu Kawaoka,* Masami Yamauchi,* Masataka Tsuge,*** Kensuke Munekage, Tsunehiro Ochi, C Nelson Hayes,* Michio Imamura,* Hiroshi Aikata,* Hirokazu Takahashi, Takuji Torimura and Kazuaki Chayama Article Title: An on-line support tool to reduce exercise-related hypoglycaemia and improve confidence to exercise in type 1 diabetes. Article Snippet: Conflict of Interest Statement: None of the authors hav ⁎ Corresponding author at: SydneyMedical School and C versity of Sydney, NSW 2006, Australia.. E-mail address: Stephen.twigg@sydney.edu.au (S.M.. T https://doi.org/10.1016/j.jdiacomp.2019.05.011 Article Title: Effects of fixed-dose mitiglinide/voglibose combination on vascular endothelial function and glycemic variability in patients with type 2 diabetes: A randomized controlled trial Article Snippet: The subjects were issued with a CGM system (iPro2 [Medtronic MiniMed, Northridge, CA] was used until October 2021; Guardian Connect [Medtronic MiniMed, Northridge, CA] was used in and after November 2021) to monitor glycemic excursions throughout each study period (the evaluation period was the last 72 hours of each period). Diagnostic Assay:Article Title: Defining continuous glucose monitor time in range in a large community-based cohort without diabetes. Article Snippet: Our observed proportion of time spent >180mg/dL was not shown in some smaller studies of 25 normoglycemic adults (n<100) wearing Dexcom G6 sensors by Shah et al.(3) or Abbott’s Freestyle Libre Pro 26 factory-calibrated sensors. (10) However, other studies have observed participants without diabetes achieving 27 glucose levels >180mg/dL, using the Freestyle Libre and iPro2 (Medtronic). (11-13) Direct comparisons are 28 AC CE PT ED M AN US CR IP T D ow nloaded from https://academ ic.oup.com /jcem /advance-article/doi/10.1210/clinem /dgae626/7754867 by guest on 12 Septem ber 2024 difficult because these studies did not always report the average times spent in those ranges. Article Title: Enlarged glycemic variability in sulfonylurea-treated well-controlled type 2 diabetics identified using continuous glucose monitoring Article Snippet: The CGM devices used were Gold (CGMS System Gold, Medtronic Inc.; Fridley, MN) and iPro2 (Medtronic MiniMed Inc.; Northridge, CA). Article Title: Effect of a single bout of morning or afternoon exercise on glucose fluctuation in young healthy men Article Snippet: The day before beginning each trial, a CGMs (iPro2, Medtronic MiniMed, CA) was attached to each subject. Article Title: Real-time CGM Is Superior to Flash Glucose Monitoring for Glucose Control in Type 1 Diabetes: The CORRIDA Randomized Controlled Trial Article Snippet: All participants initiated professional (masked) CGM (iPro2; Medtronic, Inc.) and were then monitored for 6 days. Article Title: Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver disease. Article Snippet: Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver disease Yutaro Ogawa,* Takashi Nakahara,* Masafumi Ono, Takumi Kawaguchi, Hiroshi Isoda, Akira Hiramatsu,* Shinsuke Uchikawa,* Hatsue Fujino,* Eisuke Murakami,* Tomokazu Kawaoka,* Masami Yamauchi,* Masataka Tsuge,*** Kensuke Munekage, Tsunehiro Ochi, C Nelson Hayes,* Michio Imamura,* Hiroshi Aikata,* Hirokazu Takahashi, Takuji Torimura and Kazuaki Chayama Article Title: An on-line support tool to reduce exercise-related hypoglycaemia and improve confidence to exercise in type 1 diabetes. Article Snippet: Conflict of Interest Statement: None of the authors hav ⁎ Corresponding author at: SydneyMedical School and C versity of Sydney, NSW 2006, Australia.. E-mail address: Stephen.twigg@sydney.edu.au (S.M.. T https://doi.org/10.1016/j.jdiacomp.2019.05.011 Article Title: Effects of fixed-dose mitiglinide/voglibose combination on vascular endothelial function and glycemic variability in patients with type 2 diabetes: A randomized controlled trial Article Snippet: The subjects were issued with a CGM system (iPro2 [Medtronic MiniMed, Northridge, CA] was used until October 2021; Guardian Connect [Medtronic MiniMed, Northridge, CA] was used in and after November 2021) to monitor glycemic excursions throughout each study period (the evaluation period was the last 72 hours of each period). |